Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTFB.L Share News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Amphion Innovations Agrees To Amend 2014 Loan Facility (ALLISS)

Mon, 11th Mar 2019 18:11

LONDON (Alliance News) - Amphion Innovations PLC said Monday it has amended its loan facility first agreed in 2014 and then amended last October.

Amphion amended the loan interest rate to 10% per annum and agreed to give the lender 15% of the appreciation on 10.0 million of Amphion's shares in Motif Bio PLC, above 33 pence. The 15% appreciation will be cut to 10% if the loan is fully repaid by the end of March.

Amphion and the lender have now agreed to sell USD750,00 of Motif Bio shares with two-thirds of the proceeds being used to reduce the loan balance, which currently stands at USD4.1 million.

Going forward, the loan interest rate will remain at 10% but the lender will receive 15% of the future appreciation of 10.0 million Motif shares above 10p and also 15% of the appreciation in 10.0 million Polarean Imaging PLC shares above 18p.

The agreement will end in September 2021 or when Amphion has sold all of its shares in Motif and Polarean.

Amphion's pledge of 24.5 million Motif shares will continue to act as Amphion's security for the loan. Amphion retains its beneficial interest in all pledged shares, although it has transferred the legal title to the majority of these.

Shares in Amphion Innovations closed flat Monday at 0.38 pence each.

More News
17 Jul 2015 06:40

Motif Bio's Iclaprim Eligible For Incentives With New US Designation

Read more
23 Jun 2015 11:20

Motif Bio raises £22m via share placing

Biopharmaceutical company Motif Bio has raised £22m via a conditional share placing with institutional investors. The London-listed group said "the placing is conditional on securing shareholder approval and on a successful qualified infection disease product designation being given to its iclaprim

Read more
23 Jun 2015 09:28

Amphion Innovations Confident After Motif IPO, 2014 Asset Value Fall

Read more
23 Jun 2015 06:58

Motif Bio Raises GBP22 Million In Discounted Share Placing (ALLISS)

Read more
9 Jun 2015 08:27

Motif Bio Annual Loss Widened Slightly Ahead Of London IPO

Read more
1 Jun 2015 11:15

Motif Bio signs deal with leading clinical research organisation

A wholly-owned subsidiary of antibiotic developer Motif Bio has signed letters of intent and interim agreements with a leading global clinical research organisation (CRO). Motif has agreed to invest more than $0.95m under the agreements, which must be paid by the end of July. Under the agreements,

Read more
1 Jun 2015 07:23

Motif Bio Shares Up As It Moves Towards Iclaprim Clinical Trials

Read more
28 May 2015 09:47

Motif Bio Gets FDA Minutes Confirming Phase III Plans For Iclaprim

Read more
7 May 2015 09:12

Motif Bio Exploring Funding Options For Iclaprim Trials (ALLISS)

Read more
15 Apr 2015 07:31

LONDON MORNING BRIEFING: Next And Burberry Shares In Fashion

Read more
15 Apr 2015 07:10

Amphion Shares Up As Motif Bio Gets US FDA Approval For Iclaprim Trial

Read more
2 Apr 2015 11:46

Motif Bio makes AIM debut, seeks approval for Iclaprim treatment

Clinical stage biopharmaceutical group Motif Bio began trading on AIM on Thursday, after raising £2.8m in its initial public offering. The group, whose 44.09% of issued equity is owned by Amphion, placed shares at 20p each, said it had 64,238,442 ordinary shares in issue and a market capitalisation

Read more
2 Apr 2015 08:19

BCA Marketplace, Marshall Motor And Motif Bio Begin Trading (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.